Login / Signup

Pharmacotherapy Options in the Management of Raynaud's Phenomenon.

Alicia M HinzeFredrick M Wigley
Published in: Current treatment options in rheumatology (2018)
Comparative effectiveness studies are needed to determine which therapeutic interventions are most beneficial in patients with RP. Based on the available evidence, we start with CCBs and add a phosphodiesterase inhibitor if symptoms are not controlled, or intravenous prostacyclin in the setting of severe critical digital ischemia. We may additionally add an endothelial receptor antagonist in cases of recurrent digital ulcers. A surgical sympathectomy may be used in refractory cases of digital ischemia. A digital block may also be a less invasive, but temporary, intervention allowing for titration of medical therapy.
Keyphrases
  • randomized controlled trial
  • healthcare
  • endothelial cells
  • physical activity
  • high dose
  • pulmonary arterial hypertension
  • early onset
  • stem cells
  • drug induced